NI201700170A - Modulaciãn inmune y tratamiento de tumores sãlidos con anticuerpos que se unen espec - Google Patents
Modulaciãn inmune y tratamiento de tumores sãlidos con anticuerpos que se unen especInfo
- Publication number
- NI201700170A NI201700170A NI201700170A NI201700170A NI201700170A NI 201700170 A NI201700170 A NI 201700170A NI 201700170 A NI201700170 A NI 201700170A NI 201700170 A NI201700170 A NI 201700170A NI 201700170 A NI201700170 A NI 201700170A
- Authority
- NI
- Nicaragua
- Prior art keywords
- treatment
- solid tumors
- specific
- binding antibodies
- immune modulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562184018P | 2015-06-24 | 2015-06-24 | |
| US201562249546P | 2015-11-02 | 2015-11-02 | |
| US201562250566P | 2015-11-04 | 2015-11-04 | |
| US201562263307P | 2015-12-04 | 2015-12-04 | |
| US201662331489P | 2016-05-04 | 2016-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201700170A true NI201700170A (es) | 2019-05-10 |
Family
ID=57586547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201700170A NI201700170A (es) | 2015-06-24 | 2017-12-20 | Modulaciãn inmune y tratamiento de tumores sãlidos con anticuerpos que se unen espec |
Country Status (37)
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5225069B2 (ja) * | 2005-03-23 | 2013-07-03 | ゲンマブ エー／エス | 多発性骨髄腫の治療のためのｃｄ３８に対する抗体 |
| SMT202000031T1 (it) | 2010-06-09 | 2020-03-13 | Genmab As | Anticorpi contro cd38 umano |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| KR102211837B1 (ko) | 2013-01-14 | 2021-02-03 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| EP3122173B2 (en) | 2014-03-26 | 2024-05-29 | SCR Engineers Ltd | Livestock location system |
| EP3699195A3 (en) | 2014-03-28 | 2020-11-04 | Xencor, Inc. | Bispecific antibodies that bind to cd38 and cd3 |
| US11071279B2 (en) | 2014-09-05 | 2021-07-27 | Intervet Inc. | Method and system for tracking health in animal populations |
| US10986817B2 (en) | 2014-09-05 | 2021-04-27 | Intervet Inc. | Method and system for tracking health in animal populations |
| PH12017500442B1 (en) | 2014-09-09 | 2023-05-24 | Janssen Biotech Inc | Combination therapies with anti-cd38 antibodies |
| EP3223907A2 (en) | 2014-11-26 | 2017-10-04 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd38 |
| PE20171324A1 (es) | 2014-11-26 | 2017-09-11 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| CN107406506A (zh) | 2014-12-04 | 2017-11-28 | 詹森生物科技公司 | 用于治疗急性髓系白血病的抗cd38抗体 |
| EA201792546A1 (ru) | 2015-05-20 | 2018-04-30 | Янссен Байотек, Инк. | Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей |
| IL256242B2 (en) | 2015-06-22 | 2024-09-01 | Janssen Biotech Inc | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| CA3004152C (en) | 2015-11-03 | 2024-04-16 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-cd38 antibodies and their uses |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| PE20181326A1 (es) * | 2015-11-03 | 2018-08-20 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a pd-1 y sus usos |
| CA3007030A1 (en) | 2015-12-07 | 2017-06-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
| EP3464360B1 (en) | 2016-05-27 | 2025-11-12 | Agenus Inc. | Anti-tim-3 antibodies and methods of use thereof |
| JP7010854B2 (ja) | 2016-06-14 | 2022-01-26 | ゼンコア インコーポレイテッド | 二重特異性チェックポイント阻害剤抗体 |
| US20190233533A1 (en) | 2016-06-28 | 2019-08-01 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
| CN109715663B (zh) | 2016-06-28 | 2022-11-25 | Xencor股份有限公司 | 结合生长抑素受体2的异源二聚抗体 |
| KR102589422B1 (ko) * | 2017-01-09 | 2023-10-13 | 바이오뮤넥스 파마슈티컬스 | 다중특이적 항체를 제조하기 위한 폴리펩티드 링커 |
| BR112019015355A2 (pt) * | 2017-01-26 | 2020-05-19 | Sangamo Therapeutics Inc | modificação genética de células b |
| KR20250025513A (ko) * | 2017-06-08 | 2025-02-21 | 블랙 벨트 테라퓨틱스 리미티드 | Cd38 조정 항체 |
| JP7679196B2 (ja) * | 2017-06-08 | 2025-05-19 | ブラック ベルト セラピューティクス リミテッド | Ｃｄ３８調節抗体 |
| CN110997722B (zh) | 2017-06-08 | 2023-09-26 | 黑带医疗有限公司 | Cd38调节抗体 |
| EP3434692A1 (en) * | 2017-07-24 | 2019-01-30 | Encefa | Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases |
| KR102770110B1 (ko) | 2017-08-16 | 2025-02-20 | 블랙 벨트 테라퓨틱스 리미티드 | Cd38 항체 |
| CA3073085A1 (en) | 2017-08-16 | 2019-02-21 | Black Belt Therapeutics Limited | Cd38 modulating antibody |
| US11542338B2 (en) | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| MA50514A (fr) | 2017-10-31 | 2020-09-09 | Janssen Biotech Inc | Méthodes de traitement du myélome multiple à haut risque |
| JP2021502100A (ja) | 2017-11-08 | 2021-01-28 | ゼンコア インコーポレイテッド | 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体 |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| CA3096052A1 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| CA3097369A1 (en) | 2018-04-17 | 2019-10-24 | Celldex Therapeutics, Inc. | Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs |
| AU2019261293B2 (en) | 2018-04-22 | 2024-10-10 | Vence, Corp. | Livestock management system and method |
| US20240254252A1 (en) * | 2018-07-13 | 2024-08-01 | Genmab A/S | Trogocytosis-mediated therapy using cd38 antibodies |
| US20200017600A1 (en) * | 2018-07-13 | 2020-01-16 | Genmab A/S | Variants of cd38 antibody and uses thereof |
| CN109265551B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Cd38抗体、嵌合抗原受体和药物 |
| CN119818670A (zh) * | 2018-09-27 | 2025-04-15 | Musc研究发展基金会 | 治疗癌症的药物组合 |
| FR3086837B1 (fr) | 2018-10-03 | 2021-06-18 | Allflex Europe | Pince pour la manipulation d’un dispositif d’identification d’un animal et/ou de prelevement d’un tissu d’un animal comprenant des moyens de maintien a moyens d’actionnement deportes |
| IL309302B2 (en) | 2018-10-10 | 2024-11-01 | Scr Eng Ltd | Livestock dry off method and device |
| US12193413B2 (en) | 2019-02-08 | 2025-01-14 | Allflex Australia Pty Ltd | Electronic animal tag reader |
| US12144320B2 (en) | 2019-02-08 | 2024-11-19 | Allflex Australia Pty Ltd | Electronic animal identification tag reader synchronisation |
| CN113678135B (zh) | 2019-02-08 | 2025-12-19 | 奥尔弗莱克斯澳大利亚有限公司 | 牲畜位置的判定 |
| US20200308297A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses |
| US12409474B2 (en) | 2019-08-28 | 2025-09-09 | S.C.R. (Engineers) Limited | Devices for analysis of a fluid |
| US20230272105A1 (en) | 2020-01-16 | 2023-08-31 | Genmab A/S | Formulations of cd38 antibodies and uses thereof |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| USD990062S1 (en) | 2020-06-18 | 2023-06-20 | S.C.R. (Engineers) Limited | Animal ear tag |
| IL275518B (en) | 2020-06-18 | 2021-10-31 | Scr Eng Ltd | Animal tag |
| USD990063S1 (en) | 2020-06-18 | 2023-06-20 | S.C.R. (Engineers) Limited | Animal ear tag |
| IL275812B (en) | 2020-07-01 | 2022-01-01 | Scr Eng Ltd | System and method for placing devices |
| CA3192204A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| CA3200086A1 (en) | 2020-11-25 | 2022-06-02 | Identigen Limited | A system and method for tracing members of an animal population |
| JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト |
| WO2022152823A1 (en) | 2021-01-14 | 2022-07-21 | Morphosys Ag | Anti-cd38 antibodies and their uses |
| IL280374B2 (en) | 2021-01-24 | 2023-11-01 | Scr Eng Ltd | System and method for controlling animal marking |
| IL280744A (en) | 2021-02-09 | 2022-09-01 | Scr Eng Ltd | A system and method for determining animal population welfare |
| TW202302642A (zh) | 2021-03-01 | 2023-01-16 | 德商莫菲西斯公司 | 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體 |
| US11739144B2 (en) | 2021-03-09 | 2023-08-29 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and CLDN6 |
| EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
| CA206812S (en) | 2021-04-08 | 2023-04-11 | Chevillot Sas | Tag applicator for animals |
| CA206747S (en) | 2021-04-08 | 2024-12-30 | Chevillot Sas | Tag applicator for animals |
| IL283741A (en) | 2021-06-03 | 2022-07-01 | Scr Eng Ltd | A system and method for estimating greenhouse gas emissions in an environment that houses animals |
| IL310941A (en) * | 2021-08-25 | 2024-04-01 | Biograph 55 Inc | Methods for the treatment of cancer associated with immunosuppressive B cells |
| US20230330138A1 (en) * | 2022-04-14 | 2023-10-19 | Creative Medical Technologies, Inc. | Treatment of cartilage degeneration using myeloid suppressor cells and exosomes derived thereof |
| US12402596B2 (en) | 2022-05-03 | 2025-09-02 | S.C.R. (Engineers) Limited | Milk channel and feed inlet coupled thereto, and system and method for conserving wash fluid in a washing process for cleaning a milkmeter system |
| CN114805582B (zh) * | 2022-06-29 | 2022-10-04 | 上海恒润达生生物科技股份有限公司 | 抗Trop2纳米抗体及其用途 |
| TW202432177A (zh) | 2022-10-31 | 2024-08-16 | 丹麥商珍美寶股份有限公司 | Ｃｄ３８抗體及其用途 |
| WO2024126750A1 (en) * | 2022-12-15 | 2024-06-20 | F. Hoffmann-La Roche Ag | Methods for treating cancer |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| NZ542873A (en) | 2003-03-05 | 2008-07-31 | Halozyme Inc | Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA |
| JP4794301B2 (ja) | 2003-06-11 | 2011-10-19 | 中外製薬株式会社 | 抗体の製造方法 |
| KR20140066259A (ko) | 2004-02-06 | 2014-05-30 | 모르포시스 아게 | 항-ｃｄ３８ 인간 항체 및 그의 용도 |
| JP5225069B2 (ja) * | 2005-03-23 | 2013-07-03 | ゲンマブ エー／エス | 多発性骨髄腫の治療のためのｃｄ３８に対する抗体 |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| TW200745162A (en) | 2005-05-24 | 2007-12-16 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| CA2625681C (en) | 2005-10-12 | 2016-08-02 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
| PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| WO2008073160A2 (en) * | 2006-08-17 | 2008-06-19 | The Trustees Of Columbia University In The City Of New York | Methods for converting or inducing protective immunity |
| WO2008037257A2 (en) * | 2006-09-26 | 2008-04-03 | Genmab A/S | Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| ES2593484T3 (es) | 2007-03-29 | 2016-12-09 | Genmab A/S | Anticuerpos biespecíficos y métodos de producción de los mismos |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| SG190572A1 (en) | 2008-04-29 | 2013-06-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| HRP20241208T1 (hr) | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| SMT202000031T1 (it) | 2010-06-09 | 2020-03-13 | Genmab As | Anticorpi contro cd38 umano |
| EP2420253A1 (en) | 2010-08-20 | 2012-02-22 | Leadartis, S.L. | Engineering multifunctional and multivalent molecules with collagen XV trimerization domain |
| ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| HK1203971A1 (en) * | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| US9179480B2 (en) | 2012-07-24 | 2015-11-03 | Telefonaktiebolaget L M Ericsson (Publ) | Apparatus and method for dynamically selecting a random access response window value for use with random access procedures in a network |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| DK2914302T3 (en) * | 2012-11-05 | 2017-04-10 | Morphosys Ag | RADIOACTIVALLY MARKED ANTIBODY AND USES OF IT |
| BR112015027313A2 (pt) | 2013-04-29 | 2017-09-26 | Teva Pharmaceuticals Australia Pty Ltd | anticorpos anti-cd38 e fusões ao interferon alfa-2b atenuado |
| US20140356318A1 (en) * | 2013-05-28 | 2014-12-04 | Israel Barken | Adoptive cell therapy with specific regulatory lymphocytes |
| WO2014194302A2 (en) | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| EP3021866A4 (en) * | 2013-07-15 | 2017-02-22 | The Board of Trustees of the Leland Stanford Junior University | Medical uses of cd38 agonists |
| EP3066125A2 (en) * | 2013-11-06 | 2016-09-14 | Boehringer Ingelheim International GmbH | Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents |
| US9603927B2 (en) * | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| JP7382695B2 (ja) * | 2020-07-09 | 2023-11-17 | パーカーエンジニアリング株式会社 | 塗料ミスト捕集装置 |
-
2016
- 2016-06-24 EA EA201890131A patent/EA037548B1/ru unknown
- 2016-06-24 PE PE2017002833A patent/PE20181090A1/es unknown
- 2016-06-24 JP JP2017566768A patent/JP7041519B2/ja active Active
- 2016-06-24 LT LTEPPCT/US2016/039165T patent/LT3313441T/lt unknown
- 2016-06-24 DK DK16815351.8T patent/DK3313441T5/da active
- 2016-06-24 FI FIEP16815351.8T patent/FI3313441T3/fi active
- 2016-06-24 MA MA71262A patent/MA71262A/fr unknown
- 2016-06-24 UA UAA201800631A patent/UA124799C2/uk unknown
- 2016-06-24 SI SI201631806T patent/SI3313441T1/sl unknown
- 2016-06-24 AU AU2016281717A patent/AU2016281717B2/en active Active
- 2016-06-24 ES ES16815351T patent/ES2982292T3/es active Active
- 2016-06-24 MY MYPI2017704935A patent/MY193727A/en unknown
- 2016-06-24 RS RS20240308A patent/RS65347B1/sr unknown
- 2016-06-24 WO PCT/US2016/039165 patent/WO2016210223A1/en not_active Ceased
- 2016-06-24 PL PL16815351.8T patent/PL3313441T3/pl unknown
- 2016-06-24 US US15/191,808 patent/US20160376373A1/en not_active Abandoned
- 2016-06-24 EP EP24158614.8A patent/EP4385569A3/en active Pending
- 2016-06-24 KR KR1020247032639A patent/KR20240150522A/ko active Pending
- 2016-06-24 EP EP16815351.8A patent/EP3313441B1/en active Active
- 2016-06-24 PT PT168153518T patent/PT3313441T/pt unknown
- 2016-06-24 CN CN201680048975.9A patent/CN107921120A/zh active Pending
- 2016-06-24 CA CA2990620A patent/CA2990620A1/en active Pending
- 2016-06-24 HR HRP20240338TT patent/HRP20240338T1/hr unknown
- 2016-06-24 MX MX2018000261A patent/MX2018000261A/es unknown
- 2016-06-24 BR BR112017027990-8A patent/BR112017027990A2/pt not_active Application Discontinuation
- 2016-06-24 CA CA3269717A patent/CA3269717A1/en active Pending
- 2016-06-24 KR KR1020187001612A patent/KR102713847B1/ko active Active
- 2016-06-24 MD MDE20180463T patent/MD3313441T2/ro unknown
- 2016-06-24 SM SM20240127T patent/SMT202400127T1/it unknown
- 2016-06-24 HU HUE16815351A patent/HUE066300T2/hu unknown
-
2017
- 2017-12-11 IL IL256248A patent/IL256248A/en unknown
- 2017-12-14 PH PH12017502311A patent/PH12017502311A1/en unknown
- 2017-12-19 CL CL2017003275A patent/CL2017003275A1/es unknown
- 2017-12-20 NI NI201700170A patent/NI201700170A/es unknown
- 2017-12-21 DO DO2017000305A patent/DOP2017000305A/es unknown
- 2017-12-22 CO CONC2017/0013332A patent/CO2017013332A2/es unknown
- 2017-12-22 SV SV2017005607A patent/SV2017005607A/es unknown
- 2017-12-26 EC ECIEPI201784878A patent/ECSP17084878A/es unknown
- 2017-12-26 GT GT201700286A patent/GT201700286A/es unknown
-
2018
- 2018-01-08 MX MX2021012134A patent/MX2021012134A/es unknown
- 2018-01-08 MX MX2021012133A patent/MX2021012133A/es unknown
- 2018-01-23 ZA ZA2018/00476A patent/ZA201800476B/en unknown
-
2019
- 2019-12-13 CL CL2019003657A patent/CL2019003657A1/es unknown
-
2022
- 2022-02-03 JP JP2022015442A patent/JP7532428B2/ja active Active
-
2024
- 2024-07-30 JP JP2024123110A patent/JP2024153803A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201700170A (es) | Modulaciãn inmune y tratamiento de tumores sãlidos con anticuerpos que se unen espec | |
| MX2022005177A (es) | Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos. | |
| EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
| MX2018014175A (es) | Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso. | |
| EA201792413A1 (ru) | Антитела против cd71, активируемые антитела против cd71 и способы их применения | |
| MX2016003129A (es) | Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano. | |
| TN2017000470A1 (en) | Heterodimeric antibodies that bind cd3 and tumor antigens. | |
| EA201792414A1 (ru) | Антитела против cd166, активируемые антитела против cd166 и способы их применения | |
| MX370807B (es) | Anticuerpos que se unen a axl. | |
| DOP2016000224A (es) | Tratamientos combinados con anticuerpos anti-cd38 | |
| GEP20217331B (en) | Anti-tigit antibodies | |
| EA201790529A1 (ru) | Новые антитела против mfi2 и способы их применения | |
| MX2015014500A (es) | Terapia de combinacion de anticuerpos contra csf-1r y agonista de tlr9. | |
| BR112018002382A8 (pt) | Novos anticorpos anti-gvpi humano e usos dos mesmos | |
| CO2017001087A2 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 | |
| BR112019005539A2 (pt) | métodos de tratamento de lesão renal aguda | |
| MX2020002585A (es) | Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer. | |
| EA201791819A1 (ru) | Комбинированная терапия с применением конъюгата антитела против cd19 с лекарственным средством и винкристина | |
| IL283742A (en) | Novel approach for treatment of cancer using immunomodulation | |
| EA202092495A1 (ru) | МОДУЛЯТОРЫ Cot И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |